Biotech firm gets Chinese patent on plant substance cocktail for diabetes, obesity and fatty liver prevention
Chinese authorities have issued a patent to French biotech firm Valbiotis which will use plant substances to prevent a series of cardiometabolic illnesses such as diabetes and obesity.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
French biotech company Valbiotis has ensured patent protection in China for the company's active ingredient TOTUM-63 which has shown effects on a series of risk factors for type 2 diabetes, for example, according to a press statement from the firm.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EU splits on vaccine patent waivers to cast doubt on US plan
For subscribers
Chinese authorities have approved Novo Nordisk's Ozempic
For subscribers
.jpg&w=384&q=75)
